Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Por Harata, N, Sasaki, T, Osaki, H, Saito, T, Shibata, S, Muryoi, T, Takai, O, Yoshinaga, K
Publicado em 1990

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

Por Dawson, M A, Gudgin, E J, Horton, S J, Giotopoulos, G, Meduri, E, Robson, S, Cannizzaro, E, Osaki, H, Wiese, M, Putwain, S, Fong, C Y, Grove, C, Craig, J, Dittmann, A, Lugo, D, Jeffrey, P, Drewes, G, Lee, K, Bullinger, L, Prinjha, R K, Kouzarides, T, Vassiliou, G S, Huntly, B J P
Publicado em 2014